IMIGLITAZAR

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H26N2O5
Molecular Weight	470.5164
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(COC2=CC=C(CO\N=C(/CCC(O)=O)C3=CC=CC=C3)C=C2)N=C(O1)C4=CC=CC=C4

InChI

InChIKey=ULVDFHLHKNJICZ-QCWLDUFUSA-N

InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21966330 | https://www.ncbi.nlm.nih.gov/pubmed/14709878 | https://clinicaltrials.gov/ct2/show/NCT00762190 | https://clinicaltrials.gov/ct2/show/NCT00762684 | https://clinicaltrials.gov/ct2/show/NCT00759720

Imiglitazar (also known as TAK-559) is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist patented by Japanese pharmaceutical company Takeda Chemical Industries for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance, and impaired glucose tolerance. Imiglitazar shows potent hypoglycemic and hypolipidemic activity and has been studied in clinical trials in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus. Unfortunately, Imiglitazar shows hepatotoxicity and has never been marketed.

Originator

Approval Year

PubMed

Title	Date	PubMed
Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators.	2011	21966330

Patents

Sample Use Guides

In Vivo Use Guide

TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

Route of Administration: Oral

Name

Type

Language

IMIGLITAZAR

Official Name

English

TAK-559

Preferred Name

English

imiglitazar [INN]

Common Name

English

(E)-4-(((4-((5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)METHOXY)PHENYL)METHOXY)IMINO)-4-PHENYLBUTANOIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98233